文献速递胸部肿瘤

EGFR第二位点突变与其他奥希替尼耐药机制的真实世界基因组图谱及奥希替尼治疗后NSCLC的临床格局

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
PubMed 文献 · J Thorac Oncol · 2023-10-06

基于93,065例NSCLC患者的全面基因组分析数据,在8,845例EGFR驱动(L858R或19外显子缺失)NSCLC中,239例(2.7%)检出ssEGFRm,以C797(71%)、L718(15%)、G724(9.5%)最常见,且分布与驱动突变类型相关。奥希替尼治疗后CGP在19%(39/205)的病例中检出ssEGFRm,391例有治疗后数据的患者中62%接受含化疗方案、25%接受靶向治疗或临床研究药物,自奥希替尼进展起中位真实世界总生存为11.4个月。

要点

  • EGFR驱动NSCLC中ssEGFRm检出率为2.7%(239/8845),以C797(71%)、L718(15%)、G724(9.5%)为主。
  • 奥希替尼治疗后CGP检出ssEGFRm的比例为19%(39/205),on-target与off-target耐药 largely 互斥。
  • 奥希替尼进展后62%接受含化疗方案,中位真实世界总生存为11.4个月。

核心结论

  • 奥希替尼耐药格局多样,组织与液体活检可检出on-target ssEGFRm和off-target耐药。
  • 奥希替尼治疗后患者主要接受含化疗方案且结局不佳,耐药时CGP可能为治疗开发与选择提供信息。

研究设计与样本

  • 研究查询了93,065例NSCLC患者组织或血液样本的全面基因组分析(CGP)结果,检测奥希替尼EGFR第二位点耐药突变(ssEGFRm;C797、L718、G724、G796、L792)。
  • 研究查询了来自约280家美国癌症诊所的NSCLC患者电子健康记录衍生的去标识化临床基因组数据库,评估奥希替尼治疗后耐药与临床治疗结局。

主要发现

  • 在8,845例EGFR驱动(L858R或19外显子缺失)NSCLC中,239例(2.7%)检出ssEGFRm,最常见为C797(71%)、L718(15%)、G724(9.5%)。
  • ssEGFRm在不同驱动突变间分布不均,C797和G724改变强烈偏向19外显子缺失,L718、G796和L792偏向L858R。
  • 奥希替尼治疗后CGP在19%(39/205)的病例中检出ssEGFRm。
  • 在配对的前/后奥希替尼样本中,on-target和off-target耐药 largely 互斥,分别见于24%和27%的病例。
  • 391例有奥希替尼治疗后治疗数据的患者中,62%接受含化疗方案,25%接受靶向治疗或临床研究药物;自奥希替尼进展起中位真实世界总生存为11.4个月。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The emergence of osimertinib as standard of care for EGFR-mutant NSCLC has renewed the need to understand and overcome drug resistance. We sought to understand the genomics and real-world treatment landscape of NSCLC with EGFR C797S and other on- and off-target resistance mechanisms. METHODS: Comprehensive genomic profiling (CGP) results from tissue or blood samples from 93,065 patients with NSCLC were queried for osimertinib EGFR second-site resistance mutations (ssEGFRms; C797, L718, G724, G796, L792). A real-world electronic health record-derived deidentified clinicogenomic database of patients with NSCLC undergoing CGP from approximately 280 U.S. cancer clinics was queried to assess post-osimertinib resistance and clinical treatment outcomes. RESULTS: A ssEGFRm was identified in 239 of 8845 (2.7%) EGFR-driven (L858R or exon 19 deletion) NSCLCs, most frequently C797 (71%), L718 (15%), and G724 (9.5%). ssEGFRms were not equally distributed across drivers; C797 and G724 changes strongly favored exon 19 deletion and L718, G796 and L792 favored L858R. Post-osimertinib CGP detected ssEGFRm in 19% of the cases (39 of 205); in paired pre-/post-osimertinib samples, on- and off-target resistance was largely mutually exclusive and observed in 24% and 27% of the cases, respectively. Of 391 patients with post-osimertinib treatment data, 62% received a chemotherapy-based regimen, whereas 25% received a targeted therapy or clinical study drug. Median real-world overall survival was 11.4 months from osimertinib progression. CONCLUSIONS: The osimertinib resistance landscape is diverse with on-target ssEGFRm and off-target resistance detected in tissue and liquid biopsy. Post-osimertinib, patients are receiving primarily chemotherapy-based regimens with poor outcomes, and CGP at resistance may offer an opportunity to inform therapeutic development and improve treatment selection.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Rotow JK, Lee JK, Madison RW, et al. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib. J Thorac Oncol. 2023. PMID: 37806383. doi:10.1016/j.jtho.2023.09.1453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。